Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Using Viral Therapy To Reverse Liver Disease

XTALKS VITALS NEWS

Liver Failure

The viral therapy works to reverse the continuous scarring of the liver, known as liver fibrosis, which eventually results in organ failure.

Share this!

June 6, 2016 | by Sarah Massey, M.Sc.

Researchers have used a modified virus to help repair damaged hepatocytes in mice with liver disease. If it proves to be similarly effective in humans, the technique could be a much-needed treatment option for thousands of patients diagnosed with liver disease.

In the US alone, over 35,000 people die of liver disease every year. The viral therapy works to reverse the continuous scarring of the liver, known as liver fibrosis, which eventually results in organ failure.

Liver disease is often caused by exposure of hepatocytes to alcohol, or stress caused by disease. As healthy hepatocytes are damaged and die, myofibroblasts take their place by generating collagen-based scar tissue. Once the liver reaches a critical number of hepatocytes, it is unable to perform its functions and goes into liver failure.

Dr. Holger Willenbring and his colleagues at the University of California, San Francisco, developed a new technique whereby myofibroblasts could be transformed into hepatocytes using viral therapy. The researchers used a modified adeno-associated virus to deliver liver transcription factors into the myofibroblast cells of liver-damaged mice. After infection with the genetically modified virus, the transcription factor genes are integrated into the host cell’s genome, inducing the cells to transform into hepatocytes.



The researchers found that the viral therapy reduced the collagen content of the mice livers by about one third, as well as increased the number of healthy liver cells. “We think the combination of making more hepatocytes and reducing collagen is the most promising approach to treating liver fibrosis,” said Willenbring. Tweet: Making hepatocytes and reducing collagen to treat #liverfibrosis http://ctt.ec/R2d9V+

According to Vanessa Hebditch, director of communications and policy at the British Liver Trust, the research could have exciting implications for the future treatment of liver disease. “The vector used in these studies is one that has already been used in the treatment of other human diseases so this is a promising approach.”

Adeno-associated viral therapy has been tested in multiple clinical trials for diseases like cystic fibrosis, hemophilia and retinal eye conditions. Willenbring expects that it will be five years or more before the viral therapy can be tested in human liver disease patients.


Keywords: Liver Disease, Viral Therapy, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Kite Pharma Secures FDA Approval for CAR-T Immunotherapy

October 20, 2017 - Kite Pharma’s Yescarta (axicabtagene ciloleucel) has become the second CAR-T immunotherapy to be approved in the US, with an indication in treating adult patients with relapsed or refractory large B-cell lymphoma.

Featured In: Biotech News


Fallopian Tubes Found to be Site of Origin for Most Ovarian Cancers

October 20, 2017 - This year, over 22,000 women will be diagnosed with ovarian cancer but a new study conducted by researchers at Perlmutter Cancer Center at NYU Langone Health suggests that most of these malignancies begin in another part of the reproductive system: the fallopian tubes.

Featured In: Life Science News


Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.